WO2000074629A3 - Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere - Google Patents

Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere Download PDF

Info

Publication number
WO2000074629A3
WO2000074629A3 PCT/FR2000/001559 FR0001559W WO0074629A3 WO 2000074629 A3 WO2000074629 A3 WO 2000074629A3 FR 0001559 W FR0001559 W FR 0001559W WO 0074629 A3 WO0074629 A3 WO 0074629A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
cytotoxic
implementing
composition
treatment
Prior art date
Application number
PCT/FR2000/001559
Other languages
English (en)
Other versions
WO2000074629A2 (fr
Inventor
Etienne Regulier
Philippe Erbs
Original Assignee
Transgene Sa
Etienne Regulier
Philippe Erbs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Etienne Regulier, Philippe Erbs filed Critical Transgene Sa
Priority to CA002339900A priority Critical patent/CA2339900A1/fr
Priority to AU56883/00A priority patent/AU780074B2/en
Priority to EP00942167A priority patent/EP1100916A2/fr
Priority to JP2001501166A priority patent/JP2003501367A/ja
Publication of WO2000074629A2 publication Critical patent/WO2000074629A2/fr
Publication of WO2000074629A3 publication Critical patent/WO2000074629A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition destinée à la mise en oeuvre d'un traitement cytotoxique chez un mammifère comprenant: (i) une séquence d'acide nucléique codant pour tout ou partie d'une chimiokine MIP, (ii) au moins une séquence d'acide nucléique codant pour tout ou partie d'un polypeptide ayant au moins une activité cytotoxique; lesdites séquences d'acide nucléique étant placées sous le contrôle des éléments nécessaires à leur expression dans une cellule hôte dudit mammifère.
PCT/FR2000/001559 1999-06-08 2000-06-07 Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere WO2000074629A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002339900A CA2339900A1 (fr) 1999-06-08 2000-06-07 Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere
AU56883/00A AU780074B2 (en) 1999-06-08 2000-06-07 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal
EP00942167A EP1100916A2 (fr) 1999-06-08 2000-06-07 Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere
JP2001501166A JP2003501367A (ja) 1999-06-08 2000-06-07 哺乳類における細胞傷害、特に抗腫瘍または抗ウイルスの治療用の組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/07181 1999-06-08
FR9907181 1999-06-08

Publications (2)

Publication Number Publication Date
WO2000074629A2 WO2000074629A2 (fr) 2000-12-14
WO2000074629A3 true WO2000074629A3 (fr) 2001-03-22

Family

ID=9546486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001559 WO2000074629A2 (fr) 1999-06-08 2000-06-07 Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere

Country Status (5)

Country Link
EP (1) EP1100916A2 (fr)
JP (1) JP2003501367A (fr)
AU (1) AU780074B2 (fr)
CA (1) CA2339900A1 (fr)
WO (1) WO2000074629A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033514A1 (fr) 2001-10-19 2003-04-24 Vascular Biogenics Ltd. Constructions de polynucleotides, compositions pharmaceutiques et procedes de regulation negative de l'angiogenese et de therapie anticancereuse
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2003093303A1 (fr) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Ciblage de proteines pour l'apport de reactifs therapeutiques ou de diagnostic

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013321A1 (fr) * 1992-12-09 1994-06-23 Indiana University Foundation Suppression des cellules myeloides
WO1997015595A1 (fr) * 1995-10-24 1997-05-01 Smithkline Beecham Corporation Procede de mobilisation de cellules souches hematopoietiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013321A1 (fr) * 1992-12-09 1994-06-23 Indiana University Foundation Suppression des cellules myeloides
WO1997015595A1 (fr) * 1995-10-24 1997-05-01 Smithkline Beecham Corporation Procede de mobilisation de cellules souches hematopoietiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (1999 FEB) 115 (2) 335-41. *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; LU Y ET AL: "Macrophage inflammatory protein -1alpha ( MIP -1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.", XP002133388, retrieved from STN Database accession no. 1999132267 *
DILLOO ET AL: "COMBINED CHEMOKINE AND CYTOKINE GENE TRANSFER ENHANCES ANTITUMOR IMMUNITY", NATURE MEDICINE, vol. 2, 1996, pages 1090 - 1095, XP002133387 *

Also Published As

Publication number Publication date
AU780074B2 (en) 2005-02-24
EP1100916A2 (fr) 2001-05-23
AU5688300A (en) 2000-12-28
CA2339900A1 (fr) 2000-12-14
JP2003501367A (ja) 2003-01-14
WO2000074629A2 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
AU3907889A (en) Dna sequences encoding polypeptides having beta-1, 3-glucanase activity
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
IL134042A0 (en) Modified dorsal tissue affecting factor and compositions
CA2294516A1 (fr) Proteines ikk-.beta., acides nucleiques et procedes
NZ503100A (en) 2-deoxyglucose-6-phosphate (2-DOG-6-P) phosphatase DNA sequences as selection markers in plants
EP1439226A3 (fr) Séquence antisens de heparanase
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
CA2295999A1 (fr) Proteines nik, acides nucleiques et procedes correspondants
HK1007435A1 (en) Protein having cytokin type activity recombinant dna coding for this protein transformed cells and microorganisms
IL75963A0 (en) Interferon derivatives,their preparation and pharmaceutical compositions containing them
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
WO2000071078A3 (fr) Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
CA2112998A1 (fr) Genes de la polyphenol-oxydase
CA2281206A1 (fr) Genes de geranyl diphosphate synthase
CA2294566A1 (fr) Proteines ikk-.alpha., acides nucleiques et procedes
WO1998011234A3 (fr) Proteines kinases humaines
WO2000074629A3 (fr) Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere
CA2253006A1 (fr) Gene hydroxylase de beta-carotene
EP0816504A3 (fr) Facteur d'activation des plaquettes acétylhydrolase, et gène codant celui-ci
EP1108786A4 (fr) Nouvelle collectine
EP0643719A4 (fr) Sequences d'acides nucleique codant pour des sequences d'acides nucleiques qui codent pour le recepteur de l'interleukine-9, ou complementaires a ces sequences.
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000942167

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2339900

Country of ref document: CA

Ref country code: CA

Ref document number: 2339900

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09762573

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 56883/00

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000942167

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000942167

Country of ref document: EP